Opthea’s Post

New Publication: VEGF-C and -D Signaling Pathways as Potential Targets for the Treatment of Wet AMD In this month’s edition of Ophthalmology and Therapy, a scientific review was published about the growing body of evidence that in retinal diseases, such as wet AMD, the pathophysiology is broader than simply dysregulation or overproduction of VEGF-A. Despite the tremendous progress in standard-of-care intravitreal anti-VEGF-A agents, visual gains can be limited in some wet AMD patients, as shown by clinical and real-world studies.  We want to recognize and thank the authors; Ian Leitch Mike Gerometta David Eichenbaum Robert Finger Nathan Steinle Megan Baldwin To read full peer-review article:  https://lnkd.in/eu2-_Bdt Christopher Vautrinot Springer Nature Group Springer Healthcare #Opthea #maculardegeneration #AMDResearch #wetAMD #ophthalmology #medicaleducation #biopharma #eyehealth #retinaspecialists #sozinibercept

Overcoming the Wet AMD treatment gap Check out the recent article by Rahul N. Khurana, MD, published in Modern Retina. The article highlights the need for better visual outcomes in wet AMD patients, and takes a closer look at potential reasons for suboptimal results with anti-VEGF-A therapies in the real world. As patients want better vision from their treatments, the author points to potential future therapies that may address long-term poor visual outcomes by increasing treatment intervals, and innovative therapies that target alternative mechanisms of action like sozibibercept (a biological VEGF-C/D potent trap inhibitor) to further improve vision outcomes in combination with current standard-of-care anti-VEGF-A therapies. To read the full article: https://lnkd.in/eyGeJ2xY. #Opthea #maculardegeneration #AMDResearch #ophthalmology #medicaleducation #biopharma #eyehealth #sozinibercept

Opthea A$55.0m (US$36.9m) Retail Entitlement Offer Opens   Opthea is pleased to announce that the fully underwritten Retail Entitlement Offer opens at 9:00 am (Melbourne time) on 19 June 2024. The Retail Entitlement Offer, which will raise approximately A$55.0 million (US$36.9 million), will close at 5:00 pm (Melbourne time) on 10 July 2024. Prospectus and personalized application forms will be dispatched to Eligible Retail Shareholders. This Retail Entitlement Offer follows a successful Institutional Entitlement Offer and institutional Placement raising approximately A$171.5 million (US$113.2 million).   To read full press release: https://lnkd.in/e5_DdGR6 #Opthea #maculardegeneration #AMDResearch #wetAMD #ophthalmology #medicaleducation #biopharma #eyehealth #retinaspecialists #sozinibercept

In this month’s Retina Today edition, Fred Guerard, Opthea CEO, and a panel of retina experts discuss the potential of sozinibercept (OPT-302) to transform the wet AMD treatment landscape and address the unmet medical need for improved efficacy. Please click here to read the Retina Today insert online and learn more about the potential of sozinibercept (OPT-302) to redefine the treatment landscape for wet AMD.https://https://lnkd.in/eMM8bh47 #Opthea #maculardegeneration #AMDResearch #wetAMD #ophthalmology #medicaleducation #biopharma #eyehealth #retinaspecialists

Watch the Healio Video Perspective from Clinical Trials at the Summit, where Fred Guerard, CEO of Opthea, shares updates on the COAST and ShORe trials. Click here to watch the video: https://bit.ly/3VjEKHj #Opthea #maculardegeneration #AMDResearch #wetAMD #ophthalmology #medicaleducation #biopharma #eyehealth #retinaspecialists #sozinibercept

Opthea Announces Placement and Partially Underwritten Entitlement Offer to Raise up to Approximately A$227.3 million (US$150.0 million) Opthea expects the net proceeds from the Placement and Entitlement Offer, together with cash on hand, to fund the Company, through the anticipated Phase 3 topline data readouts for COAST (Combination OPT-302 with Aflibercept Study), and ShORe (Study of OPT-302 in combination with Ranibizumab). The funds are also intended to be used to progress chemistry, manufacturing, and controls (CMC) activities, Biologics License Application (BLA) preparations for FDA approval, and for general corporate purposes. Based on the completion of enrollment in COAST in February 2024 and ShORe in May 2024, as well as Opthea’s internal expansion of its clinical development team, the topline data readout of COAST is now accelerated to early in the second calendar quarter of 2025, and the topline data readout for ShORe is anticipated in mid-calendar year 2025.   To read full press release: https://lnkd.in/eufQw4Ep #Opthea #maculardegeneration #AMDResearch #wetAMD #ophthalmology #medicaleducation #biopharma #eyehealth #retinaspecialists

“I would like to express my enormous gratitude to the investigators, study site staff and all trial participants and their families. Their contributions have been instrumental in completing the enrollment of the sozinibercept Phase 3 clinical program, which brings us closer to our goal of realizing superior vision outcomes for patients with wet AMD. This is testament to the continued commitment to advancing therapeutic innovation to benefit patients with wet AMD.” To read full press release: https://lnkd.in/eHi_MF2q #Opthea #maculardegeneration #AMDResearch #wetAMD #ophthalmology #medicaleducation #biopharma #eyehealth #retinaspecialists #clinicaltrials

Thank you Modern Retina for covering this event. We are very excited about CTS Retina 2024! https://lnkd.in/euBGzDKS

Opthea today announced that the Company will make several presentations at the Clinical Trials at the Summit (CTS) Meeting being held in Park City, Utah on June 8, 2024. Frederic Guerard, PharmD, Chief Executive Officer of Opthea, will participate in a panel, there will be two scientific presentations related to the sozinibercept (OPT-302) clinical trial program and a sponsor talk.   To read full press release: https://lnkd.in/eR6X__gU  #Opthea #maculardegeneration #AMDResearch #wetAMD #ophthalmology #medicaleducation #biopharma #eyehealth #retinaspecialists